Study Identifies Factors Associated With Hearing Loss in Polycythemia Vera

ropeginterferon
Ropeginterferon alfa-2b, a novel IFNα-2b, induces high response rates with low toxicity in patients with polycythemia vera
September 20, 2016
Is a Cure for Blood Cancer Around the Corner?
October 18, 2016

Study Identifies Factors Associated With Hearing Loss in Polycythemia Vera

hearing loss in PV
[contentcards url=”http://www.oncologynurseadvisor.com/leukemia/factors-associated-with-hearing-loss-in-pv-pinpointed/article/523647/” target=”_blank”]

“Researchers found that the mean hemoglobin and hematocrit levels of the polycythemia vera group were 16.7 g/dL and 50.4%, respectively, vs 13.4 g/dL and 40.3% in control arm. These differences were not statistically significant.”

….these differences look very statistically significant to me! (comment added by MPN-CC)

“Results showed that patients with polycythemia vera had a significantly higher incidence of cochlear impairment compared with controls (P =.004).”

“However, patients with polycythemia vera had significantly higher platelet counts compared with controls (P <.001). Further, nearly three-fourths of those with the myeloproliferative disorder and cochlear involvement had a platelet count greater than 394,000/mm3 (P =.005), suggesting a significant association between platelet count and hearing impairment in this population.”

  • NOTE:  Please read the complete article by clicking on the article box above or here.

 

Comments are closed.

MPN Cancer Connection
Malcare WordPress Security